From Self-sufficiency
Jump to: navigation, search
Systematic (IUPAC) name
N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)- 2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide
CAS Number 142001-63-6
ATC code none
PubChem CID 104974
Chemical data
Formula C31H35Cl2N3O2
Molar mass 552.5345 g/mol
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Saredutant (SR-48,968) is a drug which acts as a NK2 receptor antagonist. It was under development by Sanofi-Aventis as a novel antidepressant and anxiolytic and made it to phase III clinical trials. However, in May of 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research/development projects, among which was saredutant for the treatment of major depressive disorder.[1].

See also


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

  1. Letter to the stockholders of Sanofi-Aventis on May 2009